New drug reduces nausea in bone marrow transplant patients

People who have undergone a bone marrow transplant may benefit from a new drug after a new study found it to be effective in easing post-procedural symptoms.

The drug, called aprepitant (brand name Emend), has been found to reduce nausea and sickness caused by chemotherapy and radiation after the procedure.

A team of researchers from Loyola University in the US conducted a clinical trial of the drug among bone marrow transplant patients.

It was discovered that 73 per cent of patients taking aprepitant suffered no vomiting during the study, compared to 23 per cent given a placebo.

The drug was approved in 2003 by the US Food and Drug Administration for the reduction of nausea in patients undergoing chemotherapy.

However, there have only been a few small-scale studies on the effect of the drug in people who have had a bone marrow transplant.

Lead researcher Dr Patrick Stiff presented his findings at the BMT Tandem Meetings and said: "We did not know how effective aprepitant would be for bone marrow transplant patients.

"We now believe this should become a standard part of patients' care."

Comment on this page »


Latest news

AXA PPP healthcare win at UK Customer Experience awards 2015

David Mobbs retires as CEO of Nuffield Health

King's victorious at World Transplant Games

New drug reduces nausea in bone marrow transplant patients
Connect with us on:

This site compiles with the HONcode standard for trustworthy health information